We have recently reported the discovery of an entirely new category of potent antiviral agents based on novel deoxynucleoside analogues with unusual fluorescent bicyclic furo base moieties. To probe structure-activity relationships and to seek to optimize the properties of the lead compounds, we prepared pyrro analogues of the furo systems. We herein report the synthesis, characterization and antiviral evaluation of these novel compounds.
Many nucleoside analogues with potent biological properties have arisen by substitution at the 5-position of the uracil base, particularly in the 2′-deoxyuridine series. The 5-(2-substituted-vinyl)-2′-deoxyuridines, in particular, have emerged as potent and selective inhibitors of herpesvirus replication, especially against herpes simplex virus type 1 (HSV-1) (DeClercq, 1980 (DeClercq, , 1984 . 5-Alkynyl-2′-deoxyuridines have also been studied as potential antiviral agents, the parent 5-ethynyl system being a potent inhibitor of HSV-1, herpes simplex virus type 2 (HSV-2) and vaccinia virus (VV) (DeClercq et al., 1979 (DeClercq et al., , 1980 . While examining certain long-chain 5-alkynyl-2′-deoxyuridines, we recently identified (McGuigan et al., 1999) unusual bicyclic furo structures such as 1a-1d (Figure 1 ) as potent and selective inhibitors of varicella-zoster virus (VZV) in tissue culture. Such compounds were previously known largely as synthetic byproducts in the Pd-catalysed coupling of terminal alkynes with 5-substituted pyrimidines to generate 5-alkynyl systems (Robins & Barr, 1983; Kumar et al., 1991 Kumar et al., , 1996 Eger et al., 1995) , and their biological activity was surprising. Furthermore, the novel structures we reported displayed an unusual, but very clear, structure-activity relationship (SAR), in the form of an absolute requirement for a long alkyl side-chain on the base moiety for biological activity, with C8-C10 being optimal for maximum anti-VZV potency.
Given the biological and potential medicinal interest in compounds 1a-1d and the novelty of their structure, we were interested in pursuing systematic variation in their structure to further probe SARs and to seek to optimise their therapeutic potential. Thus, in this manuscript we describe the design, synthesis and evaluation of certain pyrro analogues of the lead furo systems.
Materials and Experimental Procedures
The numbering of the bicyclic ring follows the recommended IUPAC nomenclature guidelines. The naming of compounds follows IUPAC nomenclature and/or standard accepted nomenclature for nucleoside chemistry. For thin layer chromatography, precoated aluminium backed (60 F-54, 0.2 mm thickness; supplied by E Merck AG, Darmstadt, Germany) were used and were developed by the ascending method. After solvent evaporation, compounds were detected by quenching of the fluorescence (at 254 nm or 366 nm depending on the compound) on irradiation with a UV lamp. For column chromatography, glass columns were slurry-packed in the appropriate eluent under gravity, with silica gel (C-gel 60A, 40-60 mm, Phase Sep, UK). Samples were applied as a concentrated solution in the same eluent, or pre-absorbed onto silica gel.
Fractions containing the product were identified by TLC, pooled and the solvent removed in vacuo. Flash column chromatography was performed with the aid of a hand pump. 
Introduction
1H and 13C-NMR spectra were recorded on a Bruker Avance DPX300 spectrometer (300 MHz and 75 MHz, respectively) and auto-calibrated to the deuterated solvent reference peak. All 13C-NMR spectra were proton decoupled. Mass spectra were obtained from a Fisons VG Platform 8070 micromass spectrometer. All spectra were produced by electrospray (ES+), using a mobile phase of acetonitrile/water (1:1). High resolution (accurate) mass spectra were performed by the service at the Department of Chemistry, University of Birmingham. All solvents used were anhydrous and used as supplied by Aldrich. All nucleosides and solid reagents were either dried for several hours while being heated under high vacuum over phosphorus pentoxide, or were dried by co-evaporation with dry pyridine. All glassware was oven-dried at 130°C for several hours or overnight, and allowed to cool in a desiccator or under a stream of dry nitrogen.
To a solution of 3-(2′-deoxy-β-D-ribofuranosyl)-6-hexyl-2,3-dihydrofuro[2,3-d]pyrimidin-2-one (1a) (80 mg, 0.238 mmol) in methanol (5 ml), was added 33% aqueous ammonia (5 ml). The reaction vessel was sealed and the reaction mixture heated at ~50°C for 20 h. The solvent was removed in vacuo and the crude product was purified by column chromatography using an eluent of dichloromethane:methanol (9:1). Appropriate fractions were combined and the solvent removed in vacuo to give 2a (48 mg, 60%), as a glassy solid. The product was then collected as a white powder by trituration with diethyl ether. 
pyrimidin-2-one (1b) (100 mg, 0.27 mmol) in methanol (5 ml) was added 33% aqueous ammonia (5 ml). The reaction vessel was sealed and the reaction mixture heated at ~50°C for 20 h. The solvent was removed in vacuo and the crude product was purified by column chromatography using an eluent of dichloromethane:methanol (9:1). The appropriate fractions were combined and the solvent removed in vacuo. The 2b (79 mg, 79%) was isolated as a cream powder by trituration with diethyl ether. 
3-(2′-Deoxy
To a turbid solution of 3-(2′-deoxy-β-D-ribofuranosyl)-6-decyl-2,3-dihydrofuro [2,3-d] pyrimidin-2-one (1c) (100 mg, 0.254 mmol) in methanol (5 ml) was added 30% aqueous ammonia (5 ml). The reaction vessel was sealed and the reaction mixture heated at 60°C for 26 h. The solvent was removed under high vacuum and the crude product was 
pyrimidin-2-one (1d) (95 mg, 0.226 mmol) in methanol (5 ml) was added 33% aqueous ammonia (5 ml). The reaction vessel was sealed and the reaction mixture heated at ~50°C for 64 h. The solvent was removed in vacuo and the crude product was dissolved in dichloromethane:methanol (1:1) and eluted through a layer of silica gel using an eluent of dichloromethane:methanol (9:1). The solvent was removed in vacuo and the resultant solid was recrystallized from hot dichloromethane. Compound 2d (44 mg, 49%) was isolated under suction as an off-white solid. 
To a turbid solution of 3-(2′-deoxy-β-D-ribofuranosyl)-6-decyl-2,3-dihydro [2,3-d] pyrimidin-2-one (1c) (100mg, 0.254 mmol) in methanol (4 ml) was added 40% aqueous methylamine (5 ml). The reaction vessel was sealed and the reaction mixture heated at 50-60°C for 16 h. The solvent was removed under high vacuum to obtain a pale brown oil. This was dissolved in dioxan (2 ml) one transferred into a round bottomed flask (100 ml) containing benzene (100 ml). The resulting mixture was heated under reflux using a Dean-Stark condenser in the presence of p-toluene sulphonyl chloride (2.4 mg, 0.127 mmol, 0.2 equiv.) for 30 min. The solvent was removed in vacuo to afford a brownish oil. This afforded a white solid on trituration with diethyl ether (70 mg, 65%). δ H (d 6 -DMSO): 8.52 (1H, S, H-4 N-CH 3 ) , 2×22.9, 28.1, 29.5, 29.6, 2×29.8 (9×CH 2 ), 41.3 (C-2′), 61.9 (C-5′), 70.8 (C-3′), 87.6 and 88.7 (C-1′ and C-4′), 96.9 (C-5), 108.7 (C-4a), 135.6 (C-4), 144.5 (C-6), 154.5 (C-2), 158.8 (C-7a) 
3-(2′-Deoxy-β-D-ribofuranosyl)-6-decyl-3,7-dihydro-2H-N-ethyl-pyrrolo[2,3-d] pyrimidin-2-one (3b)
To a turbid solution of 3-(2′-deoxy-β-D-ribofuranosyl)-6-decyl-2,3-dihydro [2,3-d] pyrimidin-2-one (1c) (110 mg, 0.280 mmol) in methanol (6 ml) was added 70% aqueous ethylamine (5 ml). The reaction vessel was sealed and the reaction mixture heated at 55-60°C for 15 h. The solvent was removed under high vacuum. The gummy material obtained was dissolved in dioxan (3 ml) and transferred into a round-bottomed flask (100 ml) containing benzene (25 ml). The resulting mixture was heated under reflux using a Dean-Stark condenser in the presence of p-toluene sulphonyl chloride (4 mg) for 30 min. The solvent was removed in vacuo and the crude product was purified by flash column chromatography using an eluent of dichloromethane:methanol (9:1). Two fluorescent fractions were isolated. Fast running compound (25 mg) was found to be the base cleaved off from the product. The expected product (slow running compound; 68 mg, 55%) was isolated as a white powder by trituration with diethyl ether. 
3-(2′-Deoxy
To a turbid solution of 3-(2′-deoxy-β-D-ribofuranosyl)-6-decyl-2,3-dihydro [2,3-d] pyrimidin-2-one (1c) (100 mg, 0.254 mmol) in methanol (5 ml) was added 40% aqueous n-propylamine (5 ml). The reaction vessel was heated at 80-100°C for 20 h. The solvent was removed under high vacuum. The residue obtained was dissolved in dioxan (3 ml) and transferred into a round bottomed flask (100ml) containing benzene (25 ml). The resulting mixture was heated under reflux using a Dean-Stark condenser in the presence of p-toluene sulphonyl chloride (3 mg) for 45 minutes. The solvent was removed in vacuo and the crude product was purified by flash column chromatography using an eluent of dichloromethane:methanol (9:1). Two fluorescent fractions were isolated. Fast running compound (17 mg) was found to be the base cleaved off from the product. The expected product (slow running compound; 50 mg, 45%) was isolated as a white powder by trituration with diethyl ether. 24.2, 24.4, 27.9, 29.0, 2×30.8, 30.9, 31.1, 32.8, 33 .4 (9×CH 2 and 2×Propyl-CH 2 ), 43.5 (C-2′), 63.1 (C-5′), 72.0 (C-3′), 88.8 and 89.9 (C-4′ and C-1′), 98.3 (C-5), 109.9 (C-4a), 137.0 (C-4), 145.5 (C-6), 155.7 (C-2), 159.8 (C-7a) 
To a turbid solution of 3-(2′-deoxy-β-D-ribofuranosyl)-6-decyl-2,3-dihydro [2,3-d] pyrimidin-2-one (1c) (100 mg, 0.254 mmol) in methanol (5 ml) was added 40% aqueous n-butylamine (2 ml). The reaction vessel was heated at 80-100°C for 13 h. The solvent was removed under high vacuum. The residue obtained was dissolved in dioxan (3 ml) and transferred into a round bottomed flask (100 ml) containing benzene (25 ml). The resulting mixture was heated under reflux using a Dean-Stark condenser for 30 min in the presence of p-toluene sulphonyl chloride (3 mg). The solvent was removed in vacuo and the crude product was purified by flash column chromatography using an eluent of dichloromethane:methanol (9:1). The pure product was collected as a white powder (60 mg, 53%) by trituration with diethyl ether. δ H (d 6 -DMSO): 8.53 (1H, S, H-4), 6.25 (1H, dd, J=6.2 Hz, H-1′), 5.99 (1H, S, H-5), 5.24 (1H, d, J=3.9 Hz, 3′-OH), 5.08 (1H, t, J=4.9 Hz, 5′-OH), 4.23 (1H, m, H-3′ ), 3.87-3.83 (3H, m, H-4′ and N-CH 2 ), 3.63 (2H, m, H-5′), 2.59 (2H, t, J=7.3 Hz, α-CH 2 ), 2.3 and 1.98 (2H, m, H-2′), 1.6 (4H, m, α-Me and N-CH 2 -CH 2 CH 2 CH 3 ), 1.35-1.24 (16H, m, 7×CH 2 and CH 2 -CH 2 CH 2 CH 3 ), 0.92-0.83 (6H, m, 2×CH 3 ; δ C (d 6 -DMSO): 13.6, 13.9 (CH 3 , Butyl-CH 3 ), 19.5, 22.0, 25.7, 26.9, 2×28.6, 28.7, 28.9, 31 .1, 31.2 (9×CH 2 and 3×Butyl-CH 2 ), 41.3 (C-2′), 60.9 (C-5′), 69.9 (C-3′), 86.7 and 87.7 (C-4′ and C-3′), 96.2 (C-5), 107.7 (C-4a), 134.8 (C-4), 143.2 (C-6), 153.6 (C-2), 157.6 (C-7a) 
Biological assays
Cells. Human embryonic lung (HEL) fibroblasts and E6SM human embryo fibroblast cells were grown in minimum essential medium (MEM) supplemented with 10% inactivated fetal calf serum (FCS), 1% L-glutamine and 0.3% sodium bicarbonate.
Viruses. The laboratory wild-type VZV strains Oka and YS, the thymidine kinase-deficient VZV strains 07-1 and YS-R, HSV-1 (KOS), HSV-2 (G), the thymidine kinasedeficient HSV-1 stains B-2006 and VMW 1837, human cytomegalovirus (HCMV) strains Davis and AD-169, and VV were used in the virus inhibition assays. Antiviral assays. Confluent HEL cells grown in 96-well microtitre plates were inoculated with VZV at an input of 20 p.f.u. per well or with HCMV at an input of 100 p.f.u. per well with HSV at 100 CCID 50 (50% cell culture infective doses) per well. After a 1 to 2 h incubation period, residual virus was removed and the infected cells were further incubated with MEM (supplemented with 2% inactivated FCS, 1% L-glutamine and 0.3% sodium bicarbonate) containing varying concentrations of the compounds. Antiviral activity was expressed as EC 50 (50% effective concentration), or compound concentration required to reduce viral plaque formation after 5 days (VZV) or virus-induced cytopathicity (HCMV after 7 days and HSV, VV after 3 days) by 50% compared to the untreated control.
Cytotoxicity assays. Confluent monolayers of HEL cells C McGuigan et al.
as well as growing HEL cells in 96-well microtitre plates were treated with different concentrations of the experimental drugs. Cell cultures were incubated for 3 (growing cells) or 5 (confluent cells) days. At the indicated time, the cells were typsinized and the cell number was determined using a Coulter counter. The 50% cytostatic concentration (CC 50 ) was defined as the compound concentration required to reduce the cell number by 50%. The MCC (minimal cytotoxic concentration) was defined as the compound concentration required to cause a microsopically visible alteration of normal cell morphology.
Results
In the synthesis of the target structures 2a-2d, we chose to use the parent nucleosides as synthetic starting materials, utilising the methods of Woo (Woo et al., 1996) . Thus, heating compounds 1a-1d (McGuigan et al., 1999) with aqueous methanolic ammonia in a sealed tube (Figure 1 ) produced target structures 2a-2d in moderate to good yield after purification by column chromatography. All compounds were characterized by 1 H-and 13 C-NMR, and mass spectrometry, as well as either elemental analysis or accurate mass measurement. Following on from the initial biological evaluation of 2a-2d, as discussed later, we were interested in preparing the N-alkylated analogues 3a-3d (Figure 1 ). We thus attempted to apply the above procedures, heating 1c in a sealed tube with the appropriate nalkyl amine. However, we noted that, in contrast to the above reactions with ammonia, the alkyl amine reactions did not progress directly to the target structures 3a-3d. Instead, the absence of fluorescence in the observed products, and subsequent NMR data, clearly indicated a lack of complete aromatization of the pyrro ring, the products being hydrated forms of the target structures. We could successfully dehydrate these intermediates using p-toluene sulphonic acid (PTSA) in refluxing benzene/dioxan using a Dean-Stark apparatus, to give the intended products. For practical reasons, the crude product from the amine reaction was used directly in the dehydration, to allow a one-pot conversion of 1c to 3a-3d in moderate yield. Again, these products were fully characterized by heteronuclear NMR and mass spectrometry, with exact mass measurement.
Discussion
The target bicyclic systems (2a-2d and 3a-3d) were evaluated for their ability to inhibit the replication of VZV in vitro, according to previously described method (McGuigan et al., 1999) . Data are shown in Table 1 for the activity of these compounds versus two strains of thymidine kinase-competent, and also two strains of thymidine kinase-deficient VZV, with data also included for the reference anti-herpetic agent acyclovir (ACV, 4) and for our previously reported furo compounds 1a-1d (McGuigan et al., 1999) . The EC 50 corresponds to the 50% effective concentration required to inhibit VZV plaque formation in human embryonic lung (HEL) fibroblasts by 50%. Cytotoxicity was determined by two assays (Table 1) . The data are expressed as MCC (minimal cytotoxic concentration) required to affect normal cell morphology, and CC 50 (50% cytostatic concentration) required to reduce HEL cell growth by 50%. It is clear from these data that the parent long chain bicyclic pyrro nucleosides (2a-2d) do act as inhibitors of VZV, with activity depending on the length of the alkyl side chain. As noted for the parent furo systems the optimal chain length may be ~C8-C10. However, as the data in Table 1 Table 1 . Antiviral activity and cytotoxicity data for bicyclic nucleoside analogues 2a-2d and 3a-3d, with reference data for compounds 1a-1d and 4.
*The variable heteroatom (or group) in the bicyclic ring system. †The alkyl side chain. ‡Varying degrees of inhibition noted at concentrations of 2 µM or higher. No complete inhibition observed at the highest concentrations tested (20 µM).
